TheraRadar
← Back
Data updated: Sep 20, 2026

SHANDONG

Generics
OncologyMetabolicCardiovascular Execution: Needs Improvement

SHANDONG is a generic drug manufacturer focused on Oncology, Metabolic, Cardiovascular.

2018
Since
12
Drugs
-
Trials
2
New Drugs (2yr)
Modality:

SHANDONG at a Glance

  • Growing R&D activity with 19 trials in last 2 years
  • Fast trial execution (31 months median completion)

SHANDONG's Key Drugs

SHANDONG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SHANDONG's Recent FDA Approvals

SHANDONG secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation

SHANDONG's Therapeutic Areas

SHANDONG's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 39%
0 drugs Phase 3: 6 Phase 2: 8 Phase 1: 24
Metabolic 34%
0 drugs Phase 3: 8 Phase 2: 5 Phase 1: 14
Cardiovascular 17%
2 drugs Phase 3: 2 Phase 2: 3 Phase 1: 1
Gastroenterology 6%
0 drugs Phase 3: 1 Phase 2: 3
Neurology 4%
1 drugs

SHANDONG's Top Competitors

SHANDONG's closest competitors by therapeutic-area and drug-target overlap include Takeda, Merck, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Takeda big-pharma
Metabolic, Gastroenterology, Oncology, Cardiovascular
Merck big-pharma
Oncology, Metabolic, Cardiovascular
AZURITY specialty
Cardiovascular, Oncology, Neurology, Metabolic
Baxter specialty
Cardiovascular, Oncology, Metabolic
Johnson & Johnson big-pharma
Oncology, Gastroenterology, Metabolic

SHANDONG Pipeline Snapshot

SHANDONG has 75 active clinical programs from ClinicalTrials.gov — 17 Phase 3, 19 Phase 2 and 39 Phase 1.

17
Phase 3
19
Phase 2
39
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 31 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges